Literature DB >> 3210233

Expression of an antibody Fv fragment in myeloma cells.

L Riechmann1, J Foote, G Winter.   

Abstract

The antigen binding site on antibodies is fashioned by loops at the tips of the beta-sheet framework of both heavy and light chain variable domains. A heterodimer of both variable domains (Fv fragment), incorporating loops from an anti-lysozyme antibody, was expressed and secreted from myeloma cells in good yield (8 mg/l in supernatant from roller bottles), and shown to bind lysozyme. The two subunits were found to be in dynamic equilibrium but are overwhelmingly associated at neutral pH. The small size of Fv fragments (25 x 10(3) Mr) make them attractive for structural studies, in vivo imaging, and therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3210233     DOI: 10.1016/0022-2836(88)90214-8

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.

Authors:  P C Keck; J S Huston
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

3.  Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Authors:  Gerald G Wulf; Bettina Altmann; Marita Ziepert; Francesco D'Amore; Gerhard Held; Richard Greil; Olivier Tournilhac; Thomas Relander; Andreas Viardot; Martin Wilhelm; Christian Wilhelm; Antonio Pezzutto; Josee M Zijlstra; Eric Van Den Neste; Pieternella J Lugtenburg; Jeanette K Doorduijn; Michel van Gelder; Gustaaf W van Imhoff; Florian Zettl; Friederike Braulke; Maike Nickelsen; Bertram Glass; Andreas Rosenwald; Philippe Gaulard; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper
Journal:  Leukemia       Date:  2020-05-07       Impact factor: 11.528

4.  Expression and targeting of intracellular antibodies in mammalian cells.

Authors:  S Biocca; M S Neuberger; A Cattaneo
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

5.  Backbone assignment, secondary structure and protein A binding of an isolated, human antibody VH domain.

Authors:  L Riechmann; J Davies
Journal:  J Biomol NMR       Date:  1995-09       Impact factor: 2.835

6.  Expression, purification and characterization of B72.3 Fv fragments.

Authors:  D J King; O D Byron; A Mountain; N Weir; A Harvey; A D Lawson; K A Proudfoot; D Baldock; S E Harding; G T Yarranton
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

7.  Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41.

Authors:  A A Kortt; R E Guthrie; M G Hinds; B E Power; N Ivancic; J B Caldwell; L C Gruen; R S Norton; P J Hudson
Journal:  J Protein Chem       Date:  1995-04

Review 8.  Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.

Authors:  R M Reilly; J Sandhu; T M Alvarez-Diez; S Gallinger; J Kirsh; H Stern
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 9.  Antigen recognition and targeted delivery by the single-chain Fv.

Authors:  J S Huston; M S Tai; J McCartney; P Keck; H Oppermann
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 10.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.